Showing results (501-510 of 2,810) with videos related to
Sort By:
Pageof 281
Expert Opinion on Drug Safety|March 5, 2026
Who is missing from SGLT-2 inhibitor trials? implications for drug safety and seneralizability: a systematic review and meta-analysisMohammad Ali Omrani, Bala Swetha Baskaran, Hasti Sadeghi, et al.Expert Opinion on Drug Safety|December 16, 2016
Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safetyYukiya Narita, Kei MuroExpert Opinion on Drug Safety|December 18, 2016
Deprescribing: a new goal focused on the patientJorge Enrique Machado-Alba, Andrés Gaviria-Mendoza, Manuel Enrique Machado-Duque, et al.Expert Opinion on Drug Safety|January 7, 2017
The safety of sacubitril-valsartan for the treatment of chronic heart failureJeffrey M Tyler, John R TeerlinkExpert Opinion on Drug Safety|December 7, 2016
Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel diseaseNikola Mitrev, Rupert W LeongExpert Opinion on Drug Safety|December 20, 2016
The safety of talimogene laherparepvec for the treatment of advanced melanomaAlexandra Gangi, Jonathan S ZagerExpert Opinion on Drug Safety|January 11, 2017
The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritisJ Braun, J KayExpert Opinion on Drug Safety|April 2, 2014
Do we need to worry about mycophenolate overdose?Guido Filler, Amaryllis FerrandExpert Opinion on Drug Safety|April 5, 2014
Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature reviewMarc De Hert, Johan Detraux, Joseph PeuskensExpert Opinion on Drug Safety|May 10, 2014
Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overviewFrancesco Semeraro, Francesco Morescalchi, Sarah Duse, et al.Pageof 281